The company added some great surprise for the stock market, presenting a relevant rise in most recent fiscal period with operating deficit of $-25.42 millions

As the earnings cycle of fiscal October to December 31 2022 resumes, many entities have declared their earnings. Some of them, are multiple constituents of the Major Pharmaceutical Preparations industry. And today, AKRO reported operating deficit of $-25.42 millions, for the financial fourth quarter of 2022.

This could be clearly marked as promising revelation, in absence of more convalescent comparisons. The improvement from the operating deficit compared to the comparable period a year before of $-32.439 millions. This also administers many analysts optimism about AKRO.


There was also some relief on the net loss. as the deficit has been cut from the period, a year before. This was a main verdict in the fourth quarter of 2022. Deficit was $-23.059 millions, while in the fourth quarter of 2021 $-32.424 millions.

Additionally, the company claimed as well net deficit of $-112.03 millions and for the financial period 2022, Revenues of $0.00 millions.

Major Pharmaceutical Preparations The company has decreased it's loss per share to $-2.87 from $-2.89 in the prior fiscal year, while by 0 % from $0.00 millions a year before.

Akero Therapeutics Inc is expected to report next financial recent numbers on May 05, 2023.

Akero Therapeutics Inc's Effective Tax Rate

Akero Therapeutics Inc's Revenue Growth

Other AKRO's Earnings Reports

company, contraction in the business performance all over financial span ending third quarter of 2022